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Abstract 
Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor 
recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the 
intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. 
Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model 
in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene 
expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro 
and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of 
prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both 
in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer 
xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the 
main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. 
Together, these results established that CD54 could be a novel reliable prostate CSC marker and 
provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling. 
Key words: prostate cancer; CD54; cancer stem cells; NOTCH1. 
Introduction 
Prostate cancer (PCa) has the highest incidence 
of cancer-related illness and is the second leading 
cause of cancer mortality in the U.S. [1]. An estimated 
15% of newly diagnosed prostate cancer patients have 
an advanced disease at the time of diagnosis [2]. 
Androgen deprivation therapy (ADT) has been the 
standard treatment strategy for patients with 
advanced prostate cancer [3]. However, almost all 
patients develop castration resistance and relapse 
within 18-24 months following ADT [3]. 
Chemotherapy is regarded as a milestone treatment 
approach for castration-resistant PCa patients, with 
average survival of 3-6 months [4]. 
Increasing evidence revealed the critical role of 
cancer stem cells (CSCs) or cancer-initiating cells in 
tumorigenesis of many cancers [5, 6], including 
prostate cancer [7-9]. CSCs are a small population of 
cells that have the potential to differentiate into 
various tumor cells within a specific tumor 
environment [5]. CSCs are involved in chemotherapy 
resistance and become enriched after ADT treatment, 
which leads to poor outcomes and frequent 
recurrence in cancer patients [10-12]. 
Over the past 20 years, targeted cancer therapies 
have been extensively studied and developed based 
on the accumulated understanding of cancer biology 
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[13]. Currently, precision medicine and targeted 
therapy are promising cancer treatments. Therefore, it 
is a priority to identify new CSC targets both in basic 
research and in clinical trials. The CD133+/α2β1 
integrin/CD44+ phenotype could be a potential target 
for the PCa CSC population [14]. However, the lack of 
a unique marker has limited the use of these 
combination targeting therapies for PCa CSCs. Thus, a 
more specific and unique target for PCa CSCs still 
requires identification. 
These ideal and novel unique markers for PCa 
CSCs could be used not only as CSC isolation 
diagnostic markers but also as potential therapeutic 
targets via antibodies, inhibitors, short interfering 
RNAs (siRNAs), etc. Here, we identified the PCa 
CSCs marker CD54 via generation of a novel human 
prostate cancer xenograft mouse model. CD54+ PCa 
cells had more tumorigenicity and were resistant to 
the administration of the chemotherapeutic drug 
cisplatin compared to CD54- PCa cells via activation 
of p38-Notch1 signaling. Targeting CD54 with the 
specific siRNAs suppressed CD54-induced 
p38-Notch1 signals, which resulted in the suppression 
of sphere formation by PCa cells and might represent 
a new potential therapeutic approach to suppress PCa 
CSCs. 
Materials and Methods 
Cell Lines and Primary Prostate Cancer 
Tissues. The cell lines LNCaP, RWPE-1, 22Rv1, 
DU145, and PC3 were obtained from the American 
Type Culture Collection (Rockville, MD, US). The 
prostate cancer tissues were obtained from the Second 
Affiliated Hospital of Kunming Medical College 
(Kunming, China) with informed consent. All human 
studies were reviewed and approved by the 
Institutional Review Board (IRB) of Institute of 
Biophysics, Chinese Academy of Sciences and 
conducted on the basis of the World Medical 
Association Declaration of Helsinki. Cell lines were 
used for less than 6 months after restoration and were 
routinely screened for Mycoplasma every 4 weeks. No 
genotypic authentication was conducted. Each cell 
line was used during the early passages. 
Patient-derived xenograft mouse model. Tumor 
tissues were obtained from prostate cancer patients 
following either biopsy or radical prostatectomy and 
then were washed 3 times on ice with RPMI 1640 
medium containing ampicillin (100 U/ml) and 
streptomycin (100 ug/ml). The tissue blocks were 
then morselized with scissors and dissociated in 
proteolytic (Accumax, Innovative Cell Technologies, 
Inc.), collagenolytic (200 U Type I and 20 U Type IV 
collagenase, Sigma-Aldrich) and DNase enzymes at 
37 °C for 2 to 6 hours. The cells were washed 3 times 
and then centrifuged 1000 rpm for 5 min with RPMI 
1640 at 4°C. The suspensions were then filtered with 
100, 200, and 300 nylon mesh, and cells were stained 
with PE-conjugated anti-CD54 (eBioscience) antibody 
and a lineage mixture containing Cy7-PE-conjugated 
anti-CD45 (BD PharMingen), biotin-conjugated 
anti-CD31 (eBioscience), CD68 (eBioscience) and 
H2Kd (BD PharMingen 553564) antibodies. Flow 
cytometry analysis and cell sorting were performed 
on a BD FACS Aria (Becton Dickinson). For the PDX 
model, cancer cells were resuspended in testis extracts 
to establish the PDX mouse model. 
For the preparation of testis extractions, the testis 
tissues were stripped into RMPI 1640 medium 
without serum, cut and emulsified with a 
homogenizer. The supernatant extracts were 
aliquoted into 100 µl and stored at -80°C before 
centrifugation at 12000 rpm for 20 minutes at 4 °C. 
To establish the PDX mouse model, 8- to 
10-week-old male BALB/c mice were anesthetized 
with an intraperitoneal injection of 1% sodium 
pentobarbital. The sorted prostate cancer cell 
suspension (cancer cell dissolved in testis extractions) 
was mixed on ice with extracellular matrix at a 1:1 
ratio. Approximately 200 μl of the prostate tumor 
cell/extracellular matrix suspension was 
subcutaneously injected into the flanks of male 
NOD/SCID mouse using a 31 G needle. Tumor 
growth in the mice was monitored by palpation of the 
subcutaneous nodules every 3 days. 
Knockdown of CD54 and overexpression of 
Notch-1 in prostate cancer cells. To construct a CD54 
knockdown lentivirus, the target sequences were 
designed as follows: shCD54-1: 5'- 
GCTGACGTGTGCAGTAATA-3', shCD54-2: 5'- 
GGACATACAACTGGGAAAT-3'; and shCD54-3: 5'- 
CAGCGGAAGATCAAGAAAT-3'. In brief, both the 
shCD54 and control hairpins were cloned into the 
pSICO-R vector. Production of lentiviral particles and 
transduction of CSCs was performed according to 
protocols from the RNAi consortium at MIT. Prostate 
cancer cells were transfected with lentiviral constructs 
expressing either shRNA against CD54 or shCtrl for 
24 hr. Positive cells were selected with puromycin for 
2 weeks. The CD54-expressing cell lines were 
identified using real-time PCR. 
The Notch-1 plasmid was already established in 
our lab, and the pcDNA3.1-Notch-1 plasmid was 
transfected into prostate cancer cells using 
Lipofectamine 2000 (Invitrogen). The expression of 
Notch-1 was assayed by western blot. 
Chemoresistant prostate cancer xenograft 
mouse model. Twelve non-castrated male 
NOD/SCID mice were obtained from the Animal 
Center of the Chinese Academy of Medical Science 
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(Beijing, China). To generate the xenografts, 1×106 
LNCaP cells were subcutaneously injected into the 
backs of NOD/SCID mice (n=24). When tumors 
reached a diameter of 5 mm after 3 d, the 
non-castrated mice were randomly divided into two 
groups (12 per group). Mice in the treatment group 
were intraperitoneally administered cisplatin, 
gemcitabine or docetaxel at doses of 5 mg/kg, 10 
mg/kg, or 3 mg/kg, respectively, every 3 d for 30 d. 
Mice in the control group were treated with PBS 
vehicle. The xenograft volume was measured every 5 
d. Mice were euthanized for tumor analysis after 30 d. 
Tumor Luciferase Imaging System. In a 
subcutaneous mouse model, isolated primary LNCaP 
cells from xenograft mice were labeled with 
luciferase-GFP and transplanted into secondary 
NOD/SCID mice (6 mice per group). Tumors were 
monitored with an in vivo imaging system (IVIS) 21 d 
after secondary transplantation. Photon counts of the 
imaged mice are indicated with pseudo-color scales. 
RNA Extraction and Microarray Analysis. Total 
RNA from freshly xenografted prostate tumor tissues 
from NOD/SCID mice treated with either cisplatin or 
vehicle was extracted using TRIzol reagent 
(Invitrogen, Carlsbad, CA, US) using a standard 
isopropanol/chloroform protocol. Gene expression 
patterns were analyzed with a human gene chip that 
contained clones of 35,000 human genes (GEO 
number: GSE78196) (CapitalBio Corp, Beijing, China). 
Microarray slides were scanned with a ScanArray 
4000 Microarray Analysis System (Packard 
Bioscience, Meriden, CT, US), and data were analyzed 
with data analysis software (Dapple version 0.86 
beta). Clones with normalized log ratios indicating 
2-fold upregulation or downregulation were selected. 
Real-time PCR. Total RNA from either cell lines 
or primary patient tumor samples was extracted with 
an RNA isolation kit (Tiangen Biotech, Beijing, 
China). RNA was subjected to cDNA synthesis with a 
PrimeScript RT reagent kit (Takara Bio, Shiga, Japan). 
cDNA was used as the template for real-time PCR 
analysis on an ABI 7200 analyzer (Applied 
Biosystems, Waltham, MA, US) with the fluorescent 
probe SYBR Green I (Tiangen Biotech). Relative 
expression levels of the genes were normalized to the 
housekeeping gene GAPDH. Each experiment was 
independently repeated at least 4 times. 
FACS Analysis of Cell Proliferation and 
Apoptosis. LNCaP, PC3, and primary prostate tumor 
cells were stained with anti-human CD54-PE and 
isolated on a FACSAria-III (BD Biosciences, San Jose, 
CA, US). For the BrdU cell proliferation assays, 
primary cells from prostate cancer patients were 
treated with 30 μM BrdU for 4 h. Cells were fixed, 
permeabilized, DNase-treated, and stained with 
anti-BrdU antibody per the manufacturer's 
instructions (BD Biosciences). Cells were analyzed on 
a BD Biosciences LSR II flow cytometer. 
 For apoptosis assays, shCD54- or shCtrl-treated 
primary prostate cancer cells were stained with an 
Annexin V-FITC kit (Sigma-Aldrich) according to the 
manufacturer's instructions. Briefly, cells were 
washed twice with cold PBS, digested, collected, and 
resuspended in binding buffer. Cells were stained 
with annexin V-FITC and propidium iodide 
(BioVision, Milpitas, CA, USA) and incubated for 10 
min at room temperature in the dark. After 200 μL of 
binding buffer was added, the annexin V-positive 
cells were analyzed on a FACSCalibur flow cytometer 
(BD Biosciences). Each experiment was independently 
repeated at least 3 times. 
Sphere-forming Assay. A single-cell suspension 
of prostate cancer cells was seeded at a density of 
3×103 cells/well in 6-well plates with ultra-low 
attachment surfaces (Corning, Corning, NY, US). Cells 
were cultured in DMEM/F12 media (Gibco, Waltham, 
MA, US) supplemented with 20 ng/mL bFGF, 20 
ng/mL EGF, 1% N2, 2% B27 (Invitrogen), and 100 
mg/mL streptomycin (Gibco). The number of spheres 
was calculated 2 weeks after seeding. Each assay was 
repeated at least 3 times. 
Colony Formation Assay. Prostate cancer cells 
were suspended in soft agar and culture media in 
6-well plates at a density of 1,000 cells/well. After 2–3 
weeks, the number of colonies (≥10 cells) within 5 
microscope fields per well were counted and 
photographed. Each experiment was independently 
repeated at least 3 times. 
Transwell Assay. shRNA-transfected cells from 
prostate cancer patients were harvested, suspended, 
and added to the upper compartments of transwell 
inserts (8 μm pore size; Corning). Lower chambers 
were filled with RPMI-1640 (Invitrogen) 
supplemented with 10% FBS (Invitrogen). After 
incubation for 16 h, cells in the upper chamber were 
scraped away with a swab. Cells that migrated to the 
lower layer of each membrane were stained with 
crystal violet, and 5 fields per well were counted 
under a light microscope. Each assay was repeated 3 
times. 
NOTCH1 Transcription Reporter System. 
LNCaP and PC3 cells were stably transduced with the 
GFP-NOTCH1 promoter to monitor transcriptional 
activation of NOTCH1. Cells were treated for 24 h 
with either vehicle or the p38 inhibitor BIRB 796 at a 
concentration of 10 μM. FACS analysis of GFP 
expression indicated NOTCH1 transcription. Each 
experiment was independently repeated at least 3 
times. 
Western Blots. Tumor cells collected from two 
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prostate cancer patients were treated with either 
vehicle or BIRB 796 for 24 h. Cells were lysed, and 
proteins were separated using SDS-PAGE before 
transfer onto a nitrocellulose membrane. Membranes 
were blocked and then probed with primary 
antibodies and HRP-conjugated secondary antibodies 
(Sigma-Aldrich). Each experiment was independently 
repeated at least 4 times. 
Primary Antibodies. The following primary 
antibodies were used: mouse anti-human CD54 
(14-0549; eBioscience, San Diego, CA, US), mouse 
anti-human CD54-PE (12-0549; eBioscience), 
anti-activated Notch1 (Abcam, ab8925), rabbit 
anti-human HES1 (11988; Cell Signaling Technology), 
mouse anti-human phospho-p38 MAPK 
(Thr180/Tyr182) (9216; Cell Signaling Technology), 
rabbit anti-human p38 MAPK (ab197348; Abcam, 
Cambridge, UK), and mouse anti-β-actin (ab6276; 
Abcam). 
Statistical Analysis. Kaplan–Meier analysis was 
used to estimate cumulative cause-specific survival 
rates and differences in mice survival between those 
receiving shCD54 xenografts and those receiving 
shCtrl xenografts. The influence of CD54 on sphere 
and colony formation capacities was analyzed using 
Student’s t-test. In all statistical analyses, statistical 
significance in two-sided tests was indicated as P ≤ 
0.05. 
Results 
Cisplatin treatment selects for tumorigenic cells 
and upregulates CD54 expression in prostate cancer 
cells from mouse xenografts. We used a xenograft 
prostate cancer model by subcutaneously 
transplanting LNCaP cells, a human prostate cancer 
cell line, into immunocompromised NOD/SCID mice. 
Mice (n=12 per group) that were intraperitoneally 
injected with the chemotherapeutic drug cisplatin 
showed significantly reduced tumor size and volume 
30 d after treatment compared to vehicle-treated mice 
(Figure 1a-c). 
However, chemotherapy often results in drug 
resistance and increases the frequency of CSCs. To test 
whether cisplatin treatment enriched for CSCs, we 
harvested tumor cells from primary NOD/SCID mice 
that were either vehicle-treated or treated with 
cisplatin and injected these harvested cells into 
secondary NOD/SCID mice. Cells from 
cisplatin-treated tumors were more tumorigenic than 
cells from vehicle-treated tumors when transplanted 
into secondary mice recipients (Figure 1d, 6 mice per 
group, Figure S1), suggesting that cisplatin treatment 
resulted in enrichment for CSCs. 
To identify the underlying molecular mechanism 
of drug resistance in prostate CSCs, we compared the 
expression profiles of LNCaP cells with or without 
cisplatin treatment by microarray analysis. The 
microarray results showed that the expression of 
many genes significantly changed after cisplatin 
treatment (Figure 1e and f, Supplementary Table 1). 
Among these genes, CD54 had one of the greatest 
differences in expression. CD54, also known as 
ICAM-1, is particularly interesting because it is a 
membrane protein and thus a potential marker for 
prostate CSCs. 
To validate the microarray results, we performed 
real-time PCR and found that cisplatin treatment 
indeed induced significantly higher CD54 mRNA 
expression in LNCaP cells (Figure 1g). Furthermore, 
LNCaP cells treated with two other chemotherapy 
drugs, gemcitabine (GEM) and docetaxel (DOC), also 
had significantly higher CD54 expression than 
vehicle-treated cells (Figure 1h). 
Immunohistochemical staining of mouse tumors 
corroborated that CD54 expression was also higher 
after chemotherapeutic treatment (Figure 1h). 
Compared with the control prostate epithelia cell line 
RWPE-1, several other prostate cancer cell lines also 
had elevated CD54 mRNA (Figure 1i) and protein 
(Figure 1j) expression in vitro. 
CD54+ Prostate Cancer Cells Resemble Cancer 
Stem Cells. After identifying elevated CD54 
expression in cells from chemoresistant tumors, we 
next investigated the precise role of CD54 in the 
tumorigenicity of prostate CSCs. To analyze whether 
CD54 is a potential marker for prostate CSCs, we 
isolated CD54+ and CD54– cells from the two prostate 
cancer cell lines PC3 and LNCaP with a specific CD54 
antibody (Figure S2) using flow cytometry (Figure 2a). 
Sphere-forming capacity is an important feature of 
CSCs. In sphere-forming assays with isolated cells, 
CD54+ cells had a significantly increased 
sphere-forming capacity than CD54– cells (Figure 2b). 
We also found that CD54+ prostate cancer cells such as 
PC3 had a greater colony-forming ability than CD54– 
cells (Figure 2c). In addition, compared to luminal 
marker expression, basal or progenitor cell marker 
expression was relatively high in CD54+ versus CD54– 
cells (supplementary Figure S3). 
 To further clarify the role of CD54 in vivo, we 
injected isolated CD54+ or CD54– cells from four 
prostate cancer lines (PC3, LNCaP, DU145, and 
22RV1) into NOD/SCID mice. CD54+ cells from all 
cell lines developed significantly more tumors than 
CD54– cells (Supplementary Table 2). CSCs are 
resistant to many drugs, so we determined the IC50 of 
cisplatin on prostate cancer cell lines. CD54+ cancer 
cells had a significantly higher IC50, indicating that 
CD54+ cells were more drug resistant than CD54– cells 
(Figure 2d).  
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Figure 1. Differential Analysis of Gene Expression in Prostate Cancer Cells from Chemoresistant Xenografts in Mice. (a, b) NOD/SCID mice were injected 
with LNCaP prostate cancer cells. One group (n=12) was treated with 5 mg/kg of cisplatin, while the other group (n=12) was administered PBS as a control. Overall tumor sizes 
grossly differed between vehicle-treated mice and mice treated with cisplatin as determined via inspection of the whole animal and upon tumor excision after mice were 
euthanized 30 d following injection. (c) Tumor volumes from vehicle-treated mice and mice treated with cisplatin every 5 d after 5x106 cell injection during the 30 d interval. (d) 
Approximately 104 cells from DDP-treated tumors and vehicle-treated tumors were labeled with luciferase and transplanted into secondary NOD/SCID mice. Tumor formation 
was monitored with an in vivo imaging system. Pseudo-color scales indicate the photon counts of imaged mice. (e) Microarray analysis of gene expression from RNA extracted 
from combined vehicle-treated or cisplatin-treated tumors from each group. (f) Expression levels of selected genes after cisplatin treatment compared to expression levels in 
vehicle-treated cells. (g) Real-time PCR measurement of relative CD54 mRNA expression in vehicle-treated tumor cells and in tumor cells treated with cisplatin (DDP), 
gemcitabine (GEM), or docetaxel (DOC). (h) Immunohistochemical staining of CD54 expression in representative tumor tissues from vehicle-treated mice or mice treated with 
DDP, GEM, or DOC (scale bar=50 μm). (i, j) Relative CD54 mRNA and protein expression levels among the prostate cell line RWPE-1 and various prostate cancer cell lines. ** 
P < 0.01. 
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Figure 2. Cancer Stem Cell Traits of Differential Populations of CD54+ and CD54– Cells. (a) FACS histograms show separate gating for the isolation of CD54+ and 
CD54– PC3 and LNCaP cells. (b) Representative light micrograph fields and comparative quantification of the sphere-forming capacity of CD54+ and CD54– LNCaP and PC3 cells. 
(c) Representative microscope fields from colony formation assays for CD54+ and CD54– PC3 cells. (d) The cisplatin (DDP) IC50 of CD54+ and CD54– cells from the PC3, 
LNCaP, DU145, and 22RV1 prostate cancer cell lines. (e) q-PCR analysis of the expression of Hedgehog, Notch, and Wnt signaling pathway genes as well as genes involved in 
stem cell self-renewal in CD54+ and CD54– PC3 cells. (f) Representative micrographs of in situ protein expression of the key signaling pathway components HES1 and CD54 in 
DAPI-stained LNCaP and PC3 cells. ** P < 0.01. 
 
Several signaling pathways are involved in 
regulation of the tumorigenesis of CSCs, including the 
Hedgehog [15, 16], Notch [17, 18], and Wnt signaling 
pathways [19, 20]. We compared the expression of 
some key molecules within these signaling pathways 
in CD54+ and CD54– PC3 cells and found that 
members of the NOTCH1 signaling pathway 
including NOTCH1, Jagged1 and HES1 were 
significantly elevated in CD54+ cells both at the 
mRNA (Figure 2e) and protein (Figure 2f) levels, 
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indicating a close correlation with CD54 function. 
CD54 Expression is Clinically Relevant. After 
identifying the critical role of CD54+ CSCs in prostate 
tumorigenesis in mice, we further explored whether 
CD54 expression was clinically relevant in prostate 
cancer patients. Detection of CD54 expression in a 
cohort of prostate patients showed that CD54 
expression was significantly enhanced in cancer cells 
from patients with recurrent prostate cancer (Figure 
3a). We also found that stronger CD54 expression was 
related to a higher 5-year mortality in prostate cancer 
patients (Figure 3b). Detailed clinical information 
regarding these findings is shown in supplementary 
Table 3. 
 To confirm CD54 expression differences during 
prostate cancer development, we compared CD54 
expression in primary and recurrent tumors from two 
cancer patients. Data from fluorescent-activated cell 
sorting (FACS) assays (Figure 3c) and 
immunohistochemical staining (Figure 3d) showed 
increased CD54 expression after recurrence in both 
patients. Together, these data indicate CD54 
expression was positively correlated to tumor 
recurrence. 
Next we aimed to identify the function of CD54+ 
cells from prostate cancer patients. We collected 
tumor tissue from a prostate cancer patient and 
isolated CD54+ and CD54– tumor cells using FACS. 
CD54+ prostate cancer cells from both primary and 
secondary lesions had significantly stronger 
sphere-forming capacity (Figure 3e). NOD/SCID mice 
transplanted with primary or secondary CD54+ tumor 
cells from the same patient developed tumors, while 
an equal number of CD54– cells did not induce tumor 
development in these mice (Figure 3f, 6 mice per 
group). The detailed uptake rate and size of the 
primary or secondary xenografts in these mice are 
shown in Figure S4 and supplementary Table 4. In 
situ immunohistochemical analysis indicated CD54 
expression heterogeneity in both primary and 
secondary xenografts of CD54+ tumors (Figure 3g). 
CD54 Knockdown Inhibits Prostate Cancer 
Stem Cell Characteristics. Our data indicated that 
CD54+ cells showed properties of prostate CSCs. 
However, it was unknown whether CD54 was 
essential in maintaining CSC features. To explore the 
function of CD54 in prostate CSCs, we knocked down 
CD54 expression with three different shRNAs in 
LNCaP and PC3 cells. shCtrl (a non-targeting shRNA) 
was used as a negative control. Significant 
knockdown efficiency was confirmed by real-time 
PCR (Figure 4a) and FACS analysis (Figure 4b). 
Knockdown of CD54 significantly inhibited colony 
formation (Figure 4c) and decreased sphere-forming 
capacity (Figure 4d). Moreover, we confirmed that the 
addition of CD54 could increase the sphere-forming 
ability of PC3 cells. However, adding the CD54 
inhibitor DAPT significantly abolished the 
sphere-forming capacity of PC3 cells (Figure S5). 
 After in vitro confirmation, we transplanted 
either control cells or cells with stable knockdown of 
CD54 into NOD/SCID mice. CD54 silencing 
significantly reduced tumor volume (Figure 4e) and 
tumor weight (Figure 4f). Exogenous expression of 
CD54 in the knockdown cells rescued these 
reductions. To assess the potential regulation roles of 
CD54 in CSCs, we inoculated single shRNA-treated 
cells into NOD/SCID mice via limiting dilution. The 
frequency of prostate CSCs was calculated by using 
ELDA software [21] based on the ratio between the 
number of tumors and the number of injection sites. 
Cells treated with shCD54-1 showed a sharp decrease 
in the frequency of prostate CSCs, while CD54 
expression in these knockdown cells abrogated this 
decrease (Figure 4g). Because NOTCH1 signaling 
mediators were highly expressed in CD54+ cancer 
cells (Figure 2e and f), we examined whether 
NOTCH1 signaling was regulated downstream of 
CD54 in prostate CSCs. We found that NOTCH1 
signaling, including Jagged1 and HES1, but not 
NOTCH2 signaling was significantly inhibited by 
CD54 knockdown in both LNCaP and PC3 cells. 
Exogenous CD54 expression rescued this inhibition 
(Figure 4h), indicating that CD54 plays a critical role 
upstream of NOTCH1 signaling in prostate CSCs. 
Attenuated Proliferation and Increased 
Apoptosis upon CD54 Knockdown. Because CD54 
silencing suppressed the characteristics of prostate 
CSCs, we evaluated the efficacy of CD54 silencing in 
bulk prostate cancer cells. We collected tumor tissue 
from a prostate cancer patient and evaluated the 
knockdown efficacy of CD54 shRNA on cancer cells. 
BrdU staining showed that shCD54 treatment 
reduced cell proliferation by keeping significantly 
fewer cells in S phase (Figure 5a). Ki67 staining 
revealed that shCD54 treatment also kept significantly 
more cells within G0 phase (Figure 5b). Similar 
proliferation data were found in 4 other patients (data 
not shown). shCD54 also significantly increased the 
apoptosis of cells collected from two patients (Figure 
5c). Transwell assays showed that the migratory 
capacity of prostate cancer cells from both patients 
was also significantly decreased by shCD54 (Figure 
5d). 
 Because CSCs are essential in tumor 
chemoresistance, CD54 knockdown might overcome 
this resistance. To test this hypothesis, we knocked 
down CD54 in PC3 cells before adding cisplatin to the 
culture. shCD54 significantly reduced the resistance 
of PC3 cells to cisplatin (Figure 5e). We further 
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measured the IC50 of cisplatin in cancer cells from 5 
prostate cancer patients and found the shCD54 
significantly reduced the IC50 values in all 5 patient 
samples (Figure 5f). 
 
 
Figure 3. Clinical Relevance of CD54 Expression. (a) Relative CD54 mRNA expression in primary (n=24) and recurrent tumors (n=12) from prostate cancer patients. (b) 
Relative CD54 mRNA expression correlated with mortality of patients with prostate cancer by Kaplan–Meier survival analysis. (c) CD54 expression in primary and recurrent 
tumors from two prostate cancer patients. (d) Immunohistochemical analysis of in situ CD54 expression in primary and recurrent tumors from two prostate cancer patients. (e) 
Representative light micrograph of the sphere-forming capacity of CD54+ and CD54– sorted cells isolated from primary and secondary xenograft tumors of prostate cancer 
patients and quantification of the results. (f) Tumor-initiating capacity of differing numbers of different quadrants of CD54+ and CD54– tumor cells isolated from primary and 
secondary prostate cancer patient xenograft tumors of NOD/SCID mice 6 weeks after injection. Red numbers indicate number of cells injected, and red arrows indicate tumor 
formation. (g) Immunohistochemical analysis of in situ CD54 expression in both primary and secondary tumor samples collected from xenografted CD54+ tumors. H&E stained 
tissues are shown as a reference (scale bar=50 μm). ** P < 0.01. 
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Figure 4. Effects of CD54 Knockdown on Prostate Cancer Stem Cells. (a) Real-time PCR analysis of relative CD54 mRNA expression in LNCaP and PC3 cells after 
transfection with control shRNA (shCtrl) or shRNAs targeting CD54 (shCD54-1, shCD54-2, and shCD54-3). (b) FACS analysis of CD54 expression in PC3 and LNCaP cells 
transfected with shCtrl or shCD54-1. (c) Representative light microscope fields and comparative quantification of the colony formation capacity of PC3 cells after transfection 
with shCtrl, shCD54-1, shCD54-2, or shCD54-3. (d) Representative light microscope fields and comparative quantification of the sphere-forming capacity of LNCaP and PC3 
cells after transfection with shCtrl, shCD54-1, shCD54-2, or shCD54-3. (e) Tumor volume measurements, measured every 5 d, in NOD/SCID mice injected with LNCaP or PC3 
cells transfected with shCtrl, shCD54-1, or shCD54-1 with reconstitution of endogenous CD54 expression. (f) Final weight of tumors from NOD/SCID mice injected with 
LNCaP or PC3 cells transfected with shCtrl, shCD54-1, or shCD54-1 with reconstitution of endogenous CD54 expression. (g) Frequency of CSCs in LNCaP or PC3 cells 
injected into NOD/SCID mice. (h) Relative fold difference of the expression of various signaling pathway components in LNCaP and PC3 cells transfected with shCtrl, shCD54-1, 
or shCD54-1 with reconstitution of endogenous CD54 expression. * P < 0.05; ** P < 0.01. 
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Figure 5. Effects of CD54 Knockdown on Cell Proliferation and Apoptosis. (a) BrdU analysis of cell cycle progression in prostate cancer patient cells transfected with 
shCtrl or shCD54-1. (b) Ki67 analysis of cell cycle progression in prostate cancer patient cells transfected with shCtrl or shCD54-1. (c) FACS analysis of propidium iodide- and 
annexin V-stained prostate cancer patient cells (from two different patients) transfected with shCtrl or shCD54-1. (d) Representative light micrograph fields and comparative 
quantification of the migratory capacity of prostate cancer patient cells (from two different patients) transfected with shCtrl or shCD54-1 via Transwell assay. (e) Representative 
microscope fields and comparative quantification of apoptosis in vehicle-treated or cisplatin (DDP)-treated PC3 cells transfected with shCtrl or shCD54-1. Arrows indicate 
apoptotic cells. (f) The cisplatin (DDP) IC50 values of 5 prostate cancer patient cell lines transfected with shCtrl or shCD54-1. * P < 0.05; ** P < 0.01. 
 
CD54 Drives Tumor Formation via 
p38-Mediated NOTCH1 Regulation. Because of the 
relevance of NOTCH1 in CD54 signaling, we explored 
CD54-mediated signaling in further detail. Since we 
detected elevated NOTCH1 signaling in CD54+ 
compared to CD54– PC3 cells (Figure 2e and f), we 
measured NOTCH1 expression in prostate cancer cell 
lines. Compared with the prostate cell line RWPE-1, 
all prostate cancer cell lines tested expressed higher 
levels of NOTCH1 mRNA (Figure 6a). Moreover, 
NOTCH1 expression positively correlated with CD54 
expression in these cell lines. NOTCH1 and CD54 
expression were also correlated in 50 prostate cancer 
patients (Figure 6b), strongly suggesting that 
NOTCH1 is involved in CD54 signaling. 
Knockdown of CD54 in LNCaP and PC3 cells 
significantly inhibited the expression of NOTCH1 and 
HES1, a NOTCH1-targeted transcriptional repressor 
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[22, 23], and the phosphorylation of p38, a 
downstream kinase of CD54/ICAM-1 [24] (Figure 6c). 
To validate whether CD54 regulates CSCs through 
NOTCH1, we overexpressed NOTCH1 in 
CD54-silenced PC3 cells and found that NOTCH1 
overexpression significantly rescued the 
sphere-forming capacity, which was inhibited by 
CD54 knockdown alone (Figure 6d). 
 As p38 phosphorylation was linked to CD54 
signaling, we further aimed to clarify the relationship 
between p38 and NOTCH1 in prostate cancer cells. 
We transfected a GFP-tagged NOTCH1 promoter into 
LNCaP and PC3 cells and found that NOTCH1 
transcription was significantly suppressed by BIRB 
796, a p38 inhibitor (Figure 6e). Consistent with the 
cell line data, BIRB 796 inhibited p38 phosphorylation 
and NOTCH1 expression in cancer cells from two 
patients with prostate cancer (Figure 6f). 
 Next, we evaluated the therapeutic effect of 
shCD54 against prostate cancer patient tumor 
samples in mice xenografts. We treated tumor cells 
from two patients with prostate cancer with either 
shCD54 or shCtrl and transplanted the treated cells 
into 12 NOD/SCID mice. The PDX tissues were 
validated for CD54 expression by IHC before 
xenotransplantation into mice (Figure S6). CD54 
silencing significantly reduced the tumor volume 
(Figure 6g) and enhanced the survival time (Figure 
6h) of mice, indicating the potential for CD54 
knockdown as a therapy against prostate cancer. 
Discussion 
CSCs play key roles in the tumorigenesis, 
metastasis and drug resistance of many cancer types 
[5, 6]. The CSC hypothesis posits that cancers are 
maintained in a hierarchical organization of rare 
‘‘cancer stem cells’’ that divide rapidly into 
amplifying cells and differentiated tumor cells [25]. 
Due to this unique survival mechanism, this rare 
population of cells is resistant to the current 
chemotherapies because the treatments are largely 
targeted at eradicating the rapidly proliferating tumor 
bulk [26]. However, the stem cells, which express 
drug transporters, are more likely to survive. These 
cells repopulate the tumor, resulting in a 
heterogeneous tumor composed of stem cells and 
committed but variably differentiated offspring [27]. 
It has been reported that CSCs are resistant to 
chemotherapy and enriched after treatment in many 
cancer types, such as breast, lung, and liver cancer 
[28-31]. Although there are a few identified CSC 
markers [32], specific and reliable CSC markers are 
lacking for several individual cancer types. 
Furthermore, many of the known CSC markers are 
not expressed exclusively on CSCs; therefore, more 
specific CSC markers are needed for the precise 
clarification of the tumorigenic function of CSCs and 
for CSC-based targeted therapies. We used 
chemotherapy to enrich CSCs in a prostate cancer 
xenograft mouse model and performed microarray 
analyses to identify genes with elevated expression 
after chemotherapy treatment of prostate cancer cells. 
This analysis revealed CD54 as a potential marker for 
prostate CSCs. 
 CD54, also known as ICAM-1 (intercellular 
adhesion molecule 1), is an adhesion molecule 
belonging to the immunoglobulin superfamily [33]. It 
is constitutively expressed on endothelial cells and 
some immune cells at low levels [34-36]. CD54 
expression is upregulated upon cytokine stimulation 
during the inflammatory response [37, 38]. CD54 is 
also expressed in many tumor types and is involved 
in the tumorigenesis of various cancers such as lung 
cancer, breast cancer, melanoma, and myeloma 
[39-43]. Our study showed that CD54 expression is 
also upregulated in prostate cancer cells compared to 
control cells. Furthermore, CD54 expression is 
enriched after chemotherapy and may contribute to 
chemoresistance. We also identified that CD54+ 
prostate cancer cells show characteristics of CSCs both 
in vitro and in vivo. Recent studies also showed that 
CD54 is a potential CSC marker of esophageal 
squamous cell carcinoma [44], glioblastoma [45], and 
prostate cancer [45]. Together, these data suggested 
that CD54 was a reliable marker for CSCs. 
 Considering the essential role of CD54 in 
prostate CSCs, we further aimed to clarify CD54 
signaling within prostate CSCs. Many signaling 
pathways have been identified in CSCs, including the 
Hedgehog [15, 16], Notch [17, 18], and Wnt signaling 
pathways [19, 20]. In addition, the JAK/STAT 
pathway also interacts with CD54 and vascular cell 
adhesion molecule (VCAM) during the formation of 
tumor spheroids from prostate cancer stem cells [46]. 
A recent study demonstrated that the lncRNA ICR 
specifically regulates CSC properties in CD54+ 
hepatocellular carcinoma [47]. We compared the 
expression of some main signaling mediators in 
CD54+ and CD54– prostate cancer cells and identified 
NOTCH1 as a key mediator in prostate CSCs. Using 
inhibitor assays, we also found that p38 
phosphorylation occurred upstream of NOTCH1 in 
CD54 signaling. It has been reported that notch-1 
could be activated by their counterligands CD54 and 
jagged-1, which were involved in the plasticity of 
vascular niches [47]. The LFA-1/ICAM-1 interaction 
could upregulate notch signaling during T-cell 
migration [48]. Taken together, our data identified a 
critical role of the CD54–p38–NOTCH1 axis in 
prostate CSCs. 
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Figure 6. CD54 Drives Tumor Formation via p38-Mediated NOTCH1 Regulation. (a) Relative NOTCH1 mRNA expression and positive correlation between 
NOTCH1 and CD54 expression in a control prostate cell line (RWPE-1) and in prostate cancer cell lines (22Rv1, DU145, LNCaP, and PC3). (b) Positive correlation between 
NOTCH1 and CD54 expression in tumors from prostate cancer patients. (c) Western blots of active NOTCH1 and HES1 expression as well as p38 phosphorylation in LNCaP 
and PC3 cells transfected with shCtrl or shCD54-1. β-actin is shown as a loading control, and total p38 is a control for p38 phosphorylation. (d) Representative light micrograph 
fields and comparative quantification of the sphere-forming capacity of PC3 cells at primary and secondary levels after transfection with either shCD54-1 or shCD54-1 with 
subsequent exogenous expression of NOTCH1. € FACS analysis of GFP-NOTCH1 promoter expression in LNCaP and PC3 cells with or without treatment using the p38 
inhibitor BIRB 796. (f) Representative Western blots of p38 phosphorylation and NOTCH1 expression in tumor cells from two prostate cancer patients with or without BIRB 
796 treatment. (g) Tumor volume measurements of NOD/SCID mice injected with tumor cells (from two prostate cancer patients) transfected with shCtrl or shCD54-1. (h) 
Survival curves of NOD/SCID mice injected with tumor cells (from two prostate cancer patients) transfected with shCtrl or shCD54-1. * P < 0.05; ** P < 0.01. 
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Tumor samples from prostate cancer patients 
showed that CD54 expression was higher in recurrent 
and metastatic cancer cells than in primary tumors. 
CSCs play a key role in tumor metastasis [49, 50]. It 
has been proposed that CSCs can be stationary (to 
establish tumor growth) or mobile (to promote tumor 
metastasis) [51], and these two distinct populations of 
CSCs have been found in human cancer tissues [52]. 
CSCs could be induced into the epithelial 
mesenchymal transition (EMT), which allows for the 
cells to become mobile or migrating CSCs. Migrating 
CSCs cells divide asymmetrically. One daughter cell 
continues proliferating and differentiating, and the 
remaining CSC migrates a short distance before either 
undergoing a new asymmetric division or beginning 
to disseminate through blood or lymphatic vessels to 
produce a metastasis [51-53]. In addition to the 
correlation of CD54 expression with prostate cancer 
recurrence, CD54+ cells from cancer patients had 
higher tumor-initiating capacity in xenograft models 
than CD54– cells, confirming the role of CD54+ cells as 
CSCs. 
Having identified the role of CD54+ CSCs in 
prostate tumorigenesis, we used shRNA to 
knockdown CD54 expression in prostate cancer cells. 
CD54 silencing inhibited the tumorigenic capacity 
and prolonged the survival time of xenografted mice. 
Our findings provide support that the development of 
therapeutic strategies to target CD54 has promising 
potential to translate into new clinical treatment 
modalities against prostate cancer. Moreover, 
downstream p38–NOTCH1 signaling pathways can 
also be considered as targets for developing prostate 
cancer treatments. 
Conclusion 
Prostate cancer stem cells (CSCs) are considered 
one of the main reasons for tumor recurrence after 
chemotherapy. Here, we show that CD54 is a reliable 
new marker for prostate CSCs. CD54 plays a critical 
role in the self-renewal and tumorigenesis of prostate 
CSCs. Targeting CD54-Notch1 signaling could be a 
potential novel strategy for future clinical prostate 
cancer treatment. 
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